Shift in epitope dominance of IgM and IgG responses to Plasmodium falciparum MSP1 block 4

[1]  C. Blanc,et al.  Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition. , 2009, The Journal of infectious diseases.

[2]  V. A. Stewart,et al.  Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya , 2009, PloS one.

[3]  B. Aasted,et al.  Vaccination of mice with plasmids expressing processed capsid protein of foot-and-mouth disease virus--importance of dominant and subdominant epitopes for antigenicity and protection. , 2007, Vaccine.

[4]  T. Horii,et al.  Allelic dimorphism-associated restriction of recombination in Plasmodium falciparum msp1. , 2007, Gene.

[5]  R. Roden,et al.  A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. , 2007, Vaccine.

[6]  G. Hui,et al.  Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development. , 2007, Vaccine.

[7]  G. Fouda,et al.  Multiplex Assay for Simultaneous Measurement of Antibodies to Multiple Plasmodium falciparum Antigens , 2006, Clinical and Vaccine Immunology.

[8]  H. Bujard,et al.  Analysis of Antibodies Directed against Merozoite Surface Protein 1 of the Human Malaria Parasite Plasmodium falciparum , 2006, Infection and Immunity.

[9]  S. Herrera,et al.  Restricted genetic diversity of Plasmodium falciparum major merozoite surface protein 1 in isolates from Colombia. , 2005, The American journal of tropical medicine and hygiene.

[10]  C. Muller,et al.  The rationale of a peptide-conjugate vaccine against measles. , 2003, Vaccine.

[11]  O. Ferreira,et al.  Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the merozoite surface protein-1 , 2003, Malaria Journal.

[12]  Thomas A. Smith,et al.  A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. , 2002, The Journal of infectious diseases.

[13]  K. Marsh,et al.  Differential Patterns of Human Immunoglobulin G Subclass Responses to Distinct Regions of a Single Protein, the Merozoite Surface Protein 1 of Plasmodium falciparum , 2001, Infection and Immunity.

[14]  D. Lowy,et al.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. , 2000, Virology.

[15]  D. Conway,et al.  Allelic recombination and linkage disequilibrium within Msp-1 of Plasmodium falciparum, the malignant human malaria parasite. , 1999, Gene.

[16]  A. Holder,et al.  Antibodies that Inhibit Malaria Merozoite Surface Protein–1 Processing and Erythrocyte Invasion Are Blocked by Naturally Acquired Human Antibodies , 1997, The Journal of experimental medicine.

[17]  O. Kaneko,et al.  Plasmodium falciparum: variation in block 4 of the precursor to the major merozoite surface proteins in natural populations. , 1996, Experimental parasitology.

[18]  M. Alpers,et al.  Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. , 1996, The American journal of tropical medicine and hygiene.

[19]  S. P. Chang,et al.  Naturally acquired antibodies against the major merozoite surface coat protein (MSP-1) of Plasmodium falciparum acquired by residents in an endemic area of Colombia. , 1994, Memorias do Instituto Oswaldo Cruz.

[20]  O. Doumbo,et al.  A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections , 1993, Infection and immunity.

[21]  R. Oberst,et al.  Antibodies to the major merozoite surface coat protein of Plasmodium falciparum (gp195) in a human population living in a malaria-endemic area of the Philippines. , 1992, The American journal of tropical medicine and hygiene.

[22]  A. Holder,et al.  Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (Pf MSP1) of Plasmodium falciparum are associated with reduced malaria morbidity , 1992, Parasite immunology.

[23]  O. Doumbo,et al.  Human antibody response to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived , 1991, Infection and immunity.

[24]  A. Holder,et al.  A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion- inhibiting antibodies , 1990, The Journal of experimental medicine.

[25]  H. Bujard,et al.  Development of the human immune response against the major surface protein (gp190) of Plasmodium falciparum , 1989, Infection and immunity.

[26]  M. Alpers,et al.  A seroepidemiological study to evaluate the role of passive maternal immunity to malaria in infants. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  K. Tanabe,et al.  Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. , 1987, Journal of molecular biology.